Journal of Clinical Oncology, Vol 16, 2745-2751, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

F Saliba, R Hagipantelli, JL Misset, G Bastian, G Vassal, M Bonnay, P Herait, C Cote, M Mahjoubi, D Mignard and E Cvitkovic
Paul Brousse Hospital, Villejuif, France.

PURPOSE: Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study was to determine the pathophysiology of CPT-11-induced delayed-onset diarrhea and assess the efficacy of combined antidiarrheal medication in a phase II, prospective, successive-cohorts, open study. PATIENTS AND METHODS: Twenty-eight patients with advanced colorectal cancer refractory to fluorouracil (5-FU) therapy received CPT-11 350 mg/m2 every 3 weeks. The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily. Before treatment, and if late diarrhea occurred, patients underwent colon mucosal biopsies for CPT-11 and topoisomerase I levels; intestinal transit time; fecalogram; fat and protein excretion; alpha1-antitrypsin clearance; D- xylose test; blood levels for vasoactive intestinal polypeptide, glucagon, gastrin, somatostatin, prostaglandin E2, and carboxylesterase; CPT-11/SN-38 and SN-38 glucuronide pharmacokinetics; and stool cultures. RESULTS: Delayed-onset diarrhea occurred during the first three treatment cycles in 23 patients (82%). Electrolyte fecal measurements showed a negative or small osmotic gap in nine of nine patients and an increased alpha1-antitrypsin clearance in six of six patients. There were no modifications in stool cultures or hormonal dysfunction. Four of 11 patients (36%) with delayed-onset diarrhea in the first cohort responded to acetorphan, whereas nine of 10 patients (90%) responded to the combination of acetorphan and loperamide (P < .02). CONCLUSION: CPT-11-induced delayed-onset diarrhea is caused by a secretory mechanism with an exudative component. Early combined treatment with loperamide and acetorphan seems effective in controlling the diarrheal episodes.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. M. Javle, S. Cao, F. A. Durrani, L. Pendyala, D. D. Lawrence, P. F. Smith, P. J. Creaven, D. C. Noel, R. V. Iyer, and Y. M. Rustum Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil Clin. Cancer Res., February 1, 2007; 13(3): 965 - 971. [Abstract] [Full Text] [PDF]

				L. Tentori, C. Leonetti, M. Scarsella, A. Muzi, E. Mazzon, M. Vergati, O. Forini, R. Lapidus, W. Xu, A. S. Dorio, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma FASEB J, August 1, 2006; 20(10): 1709 - 1711. [Abstract] [Full Text] [PDF]

				G. Brandi, J. Dabard, P. Raibaud, M. Di Battista, C. Bridonneau, A. M. Pisi, A. M. M. Labate, M. A. Pantaleo, A. De Vivo, and G. Biasco Intestinal Microflora and Digestive Toxicity of Irinotecan in Mice Clin. Cancer Res., February 15, 2006; 12(4): 1299 - 1307. [Abstract] [Full Text] [PDF]

				O. Soepenberg, H. Dumez, J. Verweij, F. A. de Jong, M. J.A. de Jonge, J. Thomas, F. A.L.M. Eskens, R. H.N. van Schaik, J. Selleslach, J. ter Steeg, et al. Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors Clin. Cancer Res., February 15, 2005; 11(4): 1504 - 1511. [Abstract] [Full Text] [PDF]

				M. Michael, M. Brittain, J. Nagai, R. Feld, D. Hedley, A. Oza, L. Siu, and M. J. Moore Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea J. Clin. Oncol., November 1, 2004; 22(21): 4410 - 4417. [Abstract] [Full Text] [PDF]

				G. Vassal, F. Doz, D. Frappaz, K. Imadalou, E. Sicard, A. Santos, J. O'Quigley, C. Germa, M.-L. Risse, D. Mignard, et al. A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3844 - 3852. [Abstract] [Full Text] [PDF]

				C.-J. Tai, J.-H. Liu, W.-S. Chen, J.-K. Lin, W.-S. Wang, C.-C. Yen, T.-J. Chiou, and P.-M. Chen Irinotecan (CPT11) Plus High-dose 5-Fluorouracil (5-FU) and Leucovorin (LV) as Salvage Therapy for Metastatic Colorectal Cancer (MCRC) after Failed Oxaliplatin Plus 5-FU and LV: a Pilot Study in Taiwan Jpn. J. Clin. Oncol., March 1, 2003; 33(3): 136 - 140. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				T. Ikegami, L. Ha, K. Arimori, P. Latham, K. Kobayashi, S. Ceryak, Y. Matsuzaki, and B. Bouscarel Intestinal Alkalization As a Possible Preventive Mechanism in Irinotecan (CPT-11)-induced Diarrhea Cancer Res., January 1, 2002; 62(1): 179 - 187. [Abstract] [Full Text] [PDF]

				M. L. Rothenberg Irinotecan (CPT-11): Recent Developments and Future Directions-Colorectal Cancer and Beyond Oncologist, February 1, 2001; 6(1): 66 - 80. [Abstract] [Full Text]

				T. Suzuki, H. Sakai, A. Ikari, and N. Takeguchi Inhibition of Thromboxane A2-Induced Cl- Secretion by Antidiarrhea Drug Loperamide in Isolated Rat Colon J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 233 - 238. [Abstract] [Full Text]

				R. Khanna, C. L. Morton, M. K. Danks, and P. M. Potter Proficient Metabolism of Irinotecan by a Human Intestinal Carboxylesterase Cancer Res., September 1, 2000; 60(17): 4725 - 4728. [Abstract] [Full Text]

				R.B. Arbuckle, S.L. Huber, and C. Zacker The Consequences of Diarrhea Occurring During Chemotherapy for Colorectal Cancer: A Retrospective Study Oncologist, June 1, 2000; 5(3): 250 - 259. [Abstract] [Full Text]

				M. K. Ma, W. C. Zamboni, K. M. Radomski, W. L. Furman, V. M. Santana, P. J. Houghton, S. K. Hanna, A. K. Smith, and C. F. Stewart Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children with Recurrent Solid Tumors after Protracted Low-Dose Irinotecan Clin. Cancer Res., March 1, 2000; 6(3): 813 - 819. [Abstract] [Full Text]

				D. Savarese, A. Al-Zoubi, and J. Boucher Glutamine for Irinotecan Diarrhea J. Clin. Oncol., January 14, 2000; 18(2): 450 - 450. [Full Text]

				E. Wasserman, C. Cuvier, F. Lokiec, F. Goldwasser, S. Kalla, D. Mery-Mignard, M. Ouldkaci, A. Besmaine, G. Dupont-Andre, M. Mahjoubi, et al. Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics J. Clin. Oncol., June 1, 1999; 17(6): 1751 - 1751. [Abstract] [Full Text] [PDF]